An FDA advisory panel will be voting on whether or not Purdue Pharma's abuse-deterrent formulation (ADF) of oxycodone (OxyContin) "meaningfully reduced" opioid-related overdoses and deaths since it was introduced in the market 10 years ago.
Opioid crisis deepens during the COVID-19 lockdown
Opioid deaths have surged across the United States during the spread of the coronavirus pandemic; the strict lockdown measures have put many Americans out of work and taken away patients from necessary medical and mental health care.